---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-005732"
form_type: "8-K"
ticker: "LMAT"
cik: "0001158895"
company_name: "LEMAITRE VASCULAR INC"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T10:42:58.852385+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LeMaitre Q4 sales $48.9M (+19%), EPS $0.38 (+49%); declares $0.16 dividend, $50M buyback

## Summary
- Q4 2023 sales $48.9M (+19% YoY), net income $8.5M (+50%), EPS $0.38 (+49%).
- Gross margin 68.1% (+450 bps) driven by ASP increases and manufacturing efficiencies.
- Segment highlights: allografts +52%, bovine patches +18%, EMEA sales +21%.
- Full year 2024 guidance: sales $209.7-$214.3M (midpoint +10%), EPS $1.60-$1.71.
- Board declares $0.16/share dividend (payable Mar 28) and authorizes $50M share buyback.

## SEC filing metadata
- accession: 0001437749-24-005732
- form_type: 8-K
- ticker: LMAT
- cik: 0001158895
- company_name: LEMAITRE VASCULAR INC
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158895/000143774924005732/0001437749-24-005732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158895/000143774924005732/lmat20240227_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-005732
- JSON: https://secwatch.observer/filing/0001437749-24-005732.json
- Plain text: https://secwatch.observer/filing/0001437749-24-005732.txt

## Key facts
- Earnings Releases
  LEMAITRE VASCULAR INC reported the quarter ended December 31, 2023 results: revenue $48.9mm, net income $8.5mm, EPS $0.38. Guidance initiated.
  - Period: the quarter ended December 31, 2023
  - Revenue: $48.9mm
  - Net income: $8.5mm
  - EPS: $0.38
  - Guidance: initiated
  - Result: preliminary results
  source text: of vascular devices, implants and services, today reported Q4 2023 results, announced a $0.16/share quarterly dividend and provided guidance. Q4 2023 Financial Results ● Sales $48.9mm, +19% (+14% organic) vs. Q4 2022 ● Gross margin 68.1%, +450 bps ● Op. income $10.2mm, +46% ● Op. margin 21% ● Net income $8.5mm, +50% ● Earnings per diluted share $0.38, +49% ●
  evidence_url: https://www.sec.gov/Archives/edgar/data/1158895/000143774924005732/0001437749-24-005732-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.